

Beiersdorf 569,2-HCL
100718-49
6713-Dr. Lt-sch

STATUS OF CLAIMS - No amendments made

Claim 1 (previously presented)

1. A method for the treatment of rosacea which comprises applying to a patient in need thereof an effective amount of a composition consisting essentially of at least one compound selected from the group consisting of NO-synthase inhibitors and salts thereof.

Claim 2 (previously presented)

2. The method of claim 1, wherein said composition is applied in the form of a cosmetic or dermatological topical preparation.

Claim 3 (cancelled)

Claim 4 (previously presented)

4. Method according to Claim 2, wherein the preparation comprise at least one antioxidant.

Claim 5 (previously presented)

5. Method according to Claim 2, wherein the preparation comprise at least one UVA filter, at least one UVB filter, at least one inorganic pigment or a combination of both.

Claim 6 (previously presented)

6. Method according to Claim 2, wherein the preparation comprise at least one antioxidant and at least one UVA filter, at least one UVB filter, at least one inorganic pigment or a combination thereof.

Claim 7 (previously presented)

7. Method according to Claim 1, wherein said at least one compound is selected from the group of N^G-monoalkyl-L-arginine, N^G, N^G-dialkyl-L-arginine, N^G, N^{G'}-dialkyl-L-arginine and N^G-nitro-L-arginine and derivatives thereof.

Claim 8 (previously presented)

8. Method according to Claim 2, wherein said at least one compound is selected from the group consisting of N^G-monoalkyl-L-arginine, N^G, N^G-dialkyl-L-arginine, N^G, N^{G'}-dialkyl-L-arginine and N^G-nitro-L-arginine and derivatives thereof.

Claims 9 and 10 (cancelled)

Beiersdorf 569,2-HCL
100718-49
6713-Dr. Lt-sch

Claim 11 (previously presented)

11. Method according to Claim 8, wherein the preparations comprise at least one antioxidant.

Claim 12 (previously presented)

12. Method according to Claim 8, wherein the preparation comprise at least one UVA filter, at least one UVB filter, at least one inorganic pigment or a combination thereof.

Claim 13 (previously presented)

13. Method according to Claim 8, wherein the preparation comprise at least one antioxidant and at least one UVA filter, at least one UVB filter and/or at least one inorganic pigment or a combination thereof.

Claim 14 (previously presented)

14. Method of Claim 1, wherein said NO-synthase inhibitors contain an arginine radical.

Claim 15 (previously presented)

15. Method of Claim 14, wherein said compounds are applied in the form of cosmetic or dermatological topical preparation.

Claims 16-18 (cancelled)

Claim 19 (previously presented)

19. A method for the treatment of rosacea which comprises applying to a patient in need thereof a cosmetic or dermatological topical preparation consisting essentially of an effective amount of an NO-synthase inhibitor or salt thereof which is selected from the group consisting of N^G-monoethyl-L-arginine monoacetate, 2-Iminobiotin, L-N^G-(1-iminoethyl)-ornithine, S-Methylisothiourea sulphate, S-Methyl-L-thiocitrulline, L-N^G-(1-iminoethyl)lysine, 7-Nitroindazole, S,S'-1,3-Phenylene-bis(1,2-ethanediyl)-bis-isothiourea, L-Thiocitrulline, alpha-N-acetyl-N^G-nitro-L-arginine methyl ester and salts thereof.

Claim 20 (previously presented)

20. The method of claim 19, wherein said NO-synthase inhibitor is selected from the group consisting of 2-Iminobiotin, L-N^G-(1-iminoethyl)-ornithine, S-Methylisothiourea sulphate, S-Methyl-L-

Beiersdorf 569.2-HCL
100718-49
6713-Dr. Lt-sch

thiocitrulline, L-N^G-(1-iminoethyl)lysine, 7-Nitroindazole, S,S'-1,3-Phenylene-bis(1,2-ethanediyl)-bis-isothiourea, L-Thiocitrulline, and salts thereof.

Claim 21 (previously presented)

21. The method of claim 20, wherein said NO-synthase inhibitor or salt thereof further comprises L^G-Nitro-L-arginine methyl ester hydrochloride.

Claim 22 (previously presented)

22. The method of claim 20 or 21, wherein the amount of NO-synthase inhibitor is from 0.001% to 20% by weight based on the total weight of the preparation.

Claim 23 (previously presented)

23. The method of claim 22, wherein the amount of NO-synthase inhibitor is from 0.01% to 10% by weight based on the total weight of the preparation.

Claim 24 (previously presented)

24. The method of claim 23, wherein the amount of NO-synthase inhibitor is from 0.1 to 5% by weight based on the total weight of the preparation.

Claims 25-27 (cancelled)